Napo Pharmaceuticals announced that the company has not yet been provided with results from the company’s GCP vendors supporting Napo’s pivotal Phase 3 OnTarget trial. The trial is evaluating the company’s plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The top line results of the study are forthcoming. The company’s abstract outlining the design of the OnTarget trial and the neglected medical need has been accepted by the December 2023 San Antonio Breast Cancer Symposium. Diarrhea is a common side effect of targeted therapies and new treatments are needed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Animal Health Inc. (JAGX) Q3 Earnings Cheat Sheet
- Jaguar Health’s Napo to present results of quality of life survey
- Jaguar Health receives additional 180-day grace period to regain compliance
- Jaguar Health enters license, commercialization agreement with Quadri Pharma
- Jaguar Health announces issuance of U.S. patent for SBS treatment